Skip to main content
Breaking: EMA's CHMP Backs High-Dose Wegovy® (7.2 mg) for Obesity Treatment

Breaking: CHMP Recommends Approval of High-Dose Wegovy® (7.2 mg) for Obesity

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorization of a new, higher dose of Wegovy® (semaglutide 7.2 mg).

This major regulatory milestone brings a more potent option to patients in the European Union, offering the potential for significantly greater weight loss compared to the standard 2.4 mg maintenance dose.

Key Takeaways

  • New Dose Strength: 7.2 mg once weekly (previously capped at 2.4 mg).
  • Efficacy: Clinical trials demonstrated an average weight loss of 20.7%.
  • Target Audience: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities.
  • Next Step: Final approval from the European Commission is expected in early 2026.

Superior Weight Loss Results

The CHMP’s positive opinion is supported by data from the STEP UP Phase 3b trial. The study compared the efficacy of the new 7.2 mg dose against the standard 2.4 mg dose.

Key findings included:

  • Greater Weight Reduction: Patients on 7.2 mg achieved a mean weight loss of 20.7% over 72 weeks, compared to 17.5% for those on the 2.4 mg dose.
  • High Response Rate: Approximately one in three patients on the high dose achieved a weight loss of 25% or more.
  • Muscle Preservation: Data indicated that the majority of weight lost was fat mass, with muscle function remaining intact.

Closing the Gap in Obesity Care

While the standard Wegovy® dose (2.4 mg) has been a game-changer, some patients hit a "plateau" or require more intensive intervention to reach healthy weight targets. The 7.2 mg dose aims to bridge the gap between pharmacotherapy and bariatric surgery results.

Martin Holst Lange, Executive Vice President at Novo Nordisk, stated that this new option will allow more people to achieve "clinically meaningful weight loss" that can improve long-term health outcomes.

Safety & Side Effects

The safety profile of the 7.2 mg dose was found to be consistent with the GLP-1 receptor agonist class. As with lower doses, the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea). These were generally mild-to-moderate and diminished over time as patients adjusted to the medication.

What Happens Next?

A positive opinion from the CHMP is the final step before official marketing authorization. The European Commission typically follows this recommendation within 67 days. Once approved, the rollout across individual EU member states will depend on local pricing and reimbursement negotiations.

Follow E-PharmaTimes for updates on the official launch date and pricing of the 7.2 mg pen.

Disclaimer: This article is for informational purposes only and does not constitute medical or pharma advice. Wegovy® is a prescription medication. Always consult your healthcare provider regarding treatment options suitable for your medical history.

Labels:

Comments

Post a Comment

Popular posts from this blog

Transforming Healthcare: The Role of Artificial Intelligence in Pharmaceuticals and Medical Devices.

AI in Healthcare & Pharma: How Artificial Intelligence Is Transforming Drug Discovery and Medical Devices Artificial Intelligence (AI) is reshaping the global healthcare ecosystem. From drug discovery to diagnostics and patient care, AI has become the driving force behind the next wave of innovation in the pharmaceutical and medical device sectors. This article explores how AI technologies are transforming every stage of the healthcare value chain. AI in Pharmaceutical Development Accelerating Drug Discovery AI algorithms now analyze massive biological and chemical datasets to identify potential drug candidates in record time. Machine learning models predict molecular properties, toxicity levels, and drug–target interactions — drastically reducing preclinical failure rates. Major pharma companies are partnering with AI startups to shorten drug discovery timelines by up to 50%. Optimizing Clinical Trials AI supports patient selection, risk prediction, and real-time tr...
Post a Comment
Read more

Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M

The pharma monster has offered five of its ophthalmic medications to eye treatment organization Harrow for a one-time frame installment of $130 million, or more extra achievement installments of $45 million. The deal incorporates waterfall medical procedure recuperation eye drops Ilevro and Nevanac, bacterial conjunctivitis eyedrop Vigamox, irritation eye drops Maxidex and the injectable Triesence. The arrangement makes Harrow famous into "an administrative role in the U.S. ophthalmic drugs market," Imprint L. Baum, Harrow's Chief and executive, said in an assertion. "We know these items quite well and have long appreciated and respected them for the worth they have conveyed to great many U.S. eyecare experts and a huge number of their patients," Baum added. The arrangement will probably close during the main quarter of 2023. A while later, Novartis will in any case possess the items beyond the U.S. U.S. Novartis "stays focused on patients by supporting ad...
Post a Comment
Read more
Ozempic Litigation Update: Brazil Court Confirms 2026 Patent Expiry Litigation Update: Brazil Court Confirms 2026 Expiry for Ozempic Patents Posted on December 18, 2025 The global battle over GLP-1 receptor agonist patents has reached a critical milestone in South America. In a decisive move that will reshape the obesity and diabetes market, Brazilian courts have effectively confirmed that the patent exclusivity for semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) will end in March 2026 . For pharmaceutical investors, patients, and generic manufacturers, here is the breakdown of the recent litigation landscape in Brazil. The Core Decision: Extension Denied Novo Nordisk, the manufacturer of Ozempic, had sought to extend the validity of its Brazilian patents beyond the standard 20-year term. Their argument was...
Post a Comment
Read more